How many Medicare J codes for specialty drugs on the medical benefit showed price drops in Q1 2025 to Q1 2026?
Answered at 9:00 in AH118 - Chemo, Cars, & Where Health Plan Savings May be Hiding, with Brian Cotter · The Astonishing Healthcare Podcast
How many Medicare J codes for specialty drugs on the medical benefit showed price drops in Q1 2025 to Q1 2026?
Between Q1 2025 and Q1 2026, 431 drugs had price drops, with some dropping up to 99%. From Q1 2026 to Q3 2026 (first three quarters of the year), 348 drugs had price drops in the medical benefit.
Full answer and detailsRead the whole answer, key facts and every other question from this episode
In short
Between Q1 2025 and Q1 2026, 431 drugs had price drops, with some dropping up to 99%.
Brian Cotter, Founder at Bright Spot Insights · AH118 - Chemo, Cars, & Where Health Plan Savings May be Hiding, with Brian Cotter · The Astonishing Healthcare Podcast · answer at 9:00
Key takeaways
- Between Q1 2025 and Q1 2026, 431 drugs had price drops, with some dropping up to 99%.
Quote to remember
“Assume the data is incorrect until proven otherwise. You need to work through the steps to validate the data before you can start digging in and understanding what price variation you see.”
— Brian Cotter
The full answer · about 1 min
Between Q1 2025 and Q1 2026, 431 drugs had price drops, with some dropping up to 99%. From Q1 2026 to Q3 2026 (first three quarters of the year), 348 drugs had price drops in the medical benefit.
Key facts
- Oxaliplatin ASP price dropped from $2,053 in 2012 to $9.40 in Q1 2026—a 99% reduction
- One hospital listed oxaliplatin at $29,595 compared to Medicare reimbursement under $10
- Specialty drug spend now represents 55-60% of pharmacy spend
- Pharmacy spend represents 25-30% of total plan spend
- 431 drugs had price drops between Q1 2025 and Q1 2026, with drops up to 99%
People, companies and topics mentioned
More answers from this episode
- 2:34What is specialty pharmacy drug spending as a percentage of total plan spend, and how has it grown?
- 5:29What was the price drop for oxaliplatin (Eloxatin) between 2012 and Q1 2026 after converting from brand to generic?
- 12:00How much can plan sponsors save by redirecting chemotherapy patients to lower-cost, high-quality providers with direct contracts?
- 15:45Why is data validation critical when using price transparency files and claims data to identify drug pricing opportunities?
- 21:30What assumption about biosimilars entering the market is often incorrect when designing benefit programs?